Icosavax, Inc. – NASDAQ:ICVX

Add to watchlist

Market closed

Open in 2 days

-1.28%

month

+124.96%

quarter

+40.09%

year

Market Cap	769.03M
Enterprise value	185.51M

P/E	-2.62
EV/Sales	N/A
EV/EBITDA	-1.33
Price/Sales	N/A
Price/Book	1.07
PEG ratio	3.08
EPS	-2.12

Revenue	N/A
EBITDA	-105.88M
Income	-92.61M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Icosavax, Inc. (NASDAQ:ICVX): Profit margin
Dec 2022	0	-21.48M
Mar 2023	0	-22.6M
Jun 2023	0	-26.49M
Sep 2023	0	-22.04M

Icosavax Financials Estimate

Q Y

Icosavax, Inc. (NASDAQ:ICVX): Analyst Estimates
2025	1.5M	-123.12M	-8208.33%

Analysts Price target
Financials & Ratios estimates

Icosavax, Inc. (NASDAQ:ICVX): Earnings per share (EPS)
2023-05-10	-0.6	-0.6
2023-08-14	-0.6	-0.59
2023-11-14	-0.57	-0.44

Icosavax, Inc. (NASDAQ:ICVX): Debt to assets
Dec 2022	238677000	20.51M	8.6%
Mar 2023	208673000	8.59M	4.12%
Jun 2023	269026000	21.30M	7.92%
Sep 2023	251296000	18.91M	7.53%

Icosavax, Inc. (NASDAQ:ICVX): Cash Flow
Dec 2022	-9.00M	-6.74M	10.08M
Mar 2023	-21.64M	12.02M	117K
Jun 2023	-19.22M	55.82M	68.07M
Sep 2023	-18.97M	-72.65M	-208K

Icosavax alternative data

Icosavax, Inc. (NASDAQ:ICVX): Employee count
Aug 2023	60
Sep 2023	60
Oct 2023	60
Nov 2023	60
Dec 2023	60
Jan 2024	60
Feb 2024	60
Mar 2024	60
Apr 2024	60
May 2024	60
Jun 2024	60
Jul 2024	60

Icosavax
Hedge Funds Holdings Q1 2023

35.66% -46.17%

of ICVX is owned by hedge funds

32 -32

hedge funds hold ICVX stock

14.16M -18.36M

shares is hold by hedge funds

ICVX hedge funds holdings changes

Icosavax, Inc. (NASDAQ:ICVX): Insider trades (number of shares)
Period	Buy	Sel
Mar 2023	0	5000
Apr 2023	0	20443
May 2023	0	10000
Jul 2023	0	36421
Dec 2023	0	195965
Jan 2024	0	15000
Feb 2024	0	15000

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Option	1 Feb 2024	SIMPSON ADAM K. director, officer..	Common Stock	15,000	$1.04	$15,600
Sale	1 Feb 2024	SIMPSON ADAM K. director, officer..	Common Stock	15,000	$15.29	$229,380
Option	1 Feb 2024	SIMPSON ADAM K. director, officer..	Stock Option (Right to Buy)	15,000	$1.04	$15,600
Option	22 Jan 2024	SIMPSON ADAM K. director, officer..	Common Stock	93,227	$1.04	$96,956
Option	22 Jan 2024	SIMPSON ADAM K. director, officer..	Common Stock	4,789	$0.84	$4,023
Option	22 Jan 2024	SIMPSON ADAM K. director, officer..	Stock Option (Right to Buy)	93,227	$1.04	$96,956
Option	22 Jan 2024	SIMPSON ADAM K. director, officer..	Stock Option (Right to Buy)	4,789	$0.84	$4,023
Option	2 Jan 2024	SIMPSON ADAM K. director, officer..	Stock Option (Right to Buy)	15,000	$1.04	$15,600
Option	2 Jan 2024	SIMPSON ADAM K. director, officer..	Common Stock	15,000	$1.04	$15,600
Sale	2 Jan 2024	SIMPSON ADAM K. director, officer..	Common Stock	15,000	$15.67	$235,095

Icosavax
Executives

Insider	Age	Compensation
Mr. Adam K. Simpson (1975) Pres, Chief Executive Officer & Director	50	$501,990
Mr. Niranjan Kanesa-thasan M.D. (1960) Chief Medical Officer	65	$433,200
Mr. Douglas A. Holtzman M.P.H., Ph.D. (1964) Chief Scientific Officer & Sec.	61	$349,250
Ms. Cassia Cearley Ph.D. (1982) Treasurer & Chief Bus. Officer	43	$349,250

Icosavax
Latest News

Friday, 26 January 2024
17:45	ICOSAVAX INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Icosavax, Inc. - ICVX	prnewswire.com
Wednesday, 3 January 2024
14:20	ICVX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Icosavax, Inc. Is Fair to Shareholders	businesswire.com
Friday, 29 December 2023
16:19	ICOSAVAX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Icosavax, Inc. - ICVX	businesswire.com
Thursday, 14 December 2023
22:47	ICOSAVAX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Icosavax, Inc. - ICVX	businesswire.com
Wednesday, 13 December 2023
13:32	Icosavax, Inc. (ICVX) Is Up 0.10% in One Week: What You Should Know	Zacks Investment Research
13:32	Icosavax, Inc. (ICVX) Moves to Buy: Rationale Behind the Upgrade	Zacks Investment Research
Tuesday, 12 December 2023
12:55	Why AstraZeneca Is Buying Icosavax For $1.1 Billion	Investopedia
08:07	Why Is Icosavax (ICVX) Stock Up 46% Today?	InvestorPlace
07:03	Icosavax surges 45% in pre-market trading as AstraZeneca agrees takeover	Proactive Investors
04:29	AstraZeneca Will Acquire RSV Vaccine Developer Icosavax For $1.1 Billion	Forbes
02:29	AstraZeneca boosts RSV profile with $1.1bn Icosavax deal	Proactive Investors
02:16	AstraZeneca to buy RSV vaccine maker Icosavax for $1.1 bln	Reuters
Friday, 8 December 2023
11:16	Wall Street Analysts Believe Icosavax, Inc. (ICVX) Could Rally 175.87%: Here's is How to Trade	Zacks Investment Research
Monday, 4 December 2023
10:34	Icosavax, Inc. (ICVX) is on the Move, Here's Why the Trend Could be Sustainable	Zacks Investment Research
Tuesday, 19 September 2023
08:00	Icosavax to Participate in the Cantor Fitzgerald Global Healthcare Conference 2023	GlobeNewsWire
Wednesday, 24 May 2023
12:43	Icosavax (ICVX) Up on Positive VLP Vaccine Candidate Data	Zacks Investment Research
Tuesday, 23 May 2023
12:17	Why Shares of Icosavax Jumped on Tuesday	The Motley Fool
Thursday, 11 May 2023
12:11	Should You Buy Icosavax (ICVX) Ahead of Earnings?	Zacks Investment Research
Wednesday, 10 May 2023
18:59	Icosavax, Inc. (ICVX) Reports Q1 Loss, Lags Revenue Estimates	Zacks Investment Research
Tuesday, 11 April 2023
09:46	3 Biotech Stocks to Watch for Potential Breakthroughs	InvestorPlace
Thursday, 15 December 2022
20:18	Icosavax (ICVX) Up 112% on Upbeat Data From RSV Jab Study	Zacks Investment Research
Monday, 14 November 2022
21:03	Icosavax, Inc. (ICVX) Reports Q3 Loss, Lags Revenue Estimates	Zacks Investment Research
Tuesday, 8 November 2022
08:00	Icosavax to Participate in in Upcoming Investor Conferences	GlobeNewsWire
Monday, 15 August 2022
18:48	Icosavax, Inc. (ICVX) Reports Q2 Loss, Lags Revenue Estimates	Zacks Investment Research
Thursday, 31 March 2022
11:29	Why Icosavax Stock Is Soaring Today	The Motley Fool
Friday, 25 March 2022
09:16	Why Icosavax's Shares Are Trading Lower Today	Benzinga
Thursday, 11 November 2021
16:22	Icosavax to Participate in Upcoming Investor Conferences	GlobeNewsWire
Wednesday, 6 October 2021
13:19	Icosavax co-founder and UW researcher Neil King talks vaccine development in the ‘digital era'	GeekWire

Ideas & Opinions

Seeking Alpha 17 Jul 2023

Icosavax: Moderna 2.0, The Microscopic Giant In The Vaccine Arena

Frequently Asked Questions (FAQ)

When is Icosavax's next earnings date?

Unfortunately, Icosavax's (ICVX) next earnings date is currently unknown.
Does Icosavax pay dividends?

No, Icosavax does not pay dividends.
How much money does Icosavax make?

Icosavax has a market capitalization of 769.03M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 92.54% to 582K US dollars. Icosavax made a loss 88.46M US dollars in net income (profit) last year or -$0.44 on an earnings per share basis.
What is Icosavax's stock symbol?

Icosavax, Inc. is traded on the NASDAQ under the ticker symbol "ICVX".
What is Icosavax's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Icosavax?

Shares of Icosavax can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Icosavax's key executives?
Icosavax's management team includes the following people:
- Mr. Adam K. Simpson Pres, Chief Executive Officer & Director(age: 50, pay: $501,990)
- Mr. Niranjan Kanesa-thasan M.D. Chief Medical Officer(age: 65, pay: $433,200)
- Mr. Douglas A. Holtzman M.P.H., Ph.D. Chief Scientific Officer & Sec.(age: 61, pay: $349,250)
- Ms. Cassia Cearley Ph.D. Treasurer & Chief Bus. Officer(age: 43, pay: $349,250)
How many employees does Icosavax have?

As Jul 2024, Icosavax employs 60 workers.
When Icosavax went public?

Icosavax, Inc. is publicly traded company for more then 4 years since IPO on 29 Jul 2021.
What is Icosavax's official website?

The official website for Icosavax is icosavax.com.
Where are Icosavax's headquarters?

Icosavax is headquartered at 1616 Eastlake Avenue East, Seattle, WA.
How can i contact Icosavax?

Icosavax's mailing address is 1616 Eastlake Avenue East, Seattle, WA and company can be reached via phone at +20 67 370085.

Icosavax, Inc.

icosavax.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases. The company, with the help of its virus-like particle (VLP) platform technology, focuses primarily on life-threatening respiratory diseases. Its products in pipeline include IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; IVX-A12, a respiratory syncytial virus (RSV) monovalent antigen candidate with RSV/human metapneumovirus (hMPV) bivalent target indication; IVX-241, a vaccine candidate with hMPV target; and IVX-411, an original receptor binding domain (RBD) sequence antigen with SARS-CoV-2 target indication and is under Phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in Seattle, Washington.

+20 67 370085

1616 Eastlake Avenue East
Seattle, WA 98102

CIK: 0001786255
ISIN: US45114M1099
CUSIP: 45114M109